Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0462 • ACR Convergence 2024
Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Carlos Hunter¹, Punyasha Roul², Joshua Baker³, grant Cannon⁴, Beth Wallace⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Isaac Smith⁹, John Richards¹⁰, Katherine Wysham¹¹, Gary Kunkel¹², Iris Lee¹³, Daniel Anderson¹⁴, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶VA Boston Healthcare System, Boston, MA, ⁷Dallas VA Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Duke University Hospital, Durham, NC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Nebraska Medical Center, Durham, NC
Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…
Abstract Number: 0478 • ACR Convergence 2024
Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity
Carolina Ramirez, Annette Oeser, Rachelle Crescenzi, C. Michael Stein and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Sodium is stored in tissues such as the skin where it may contribute to development and progression of autoimmune diseases and hypertension through activation…
Abstract Number: 0496 • ACR Convergence 2024
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Nils Steinz¹, Tjardo Maarseveen², Andrew Cope³, John Isaacs⁴, Aaron Winkler⁵, Thomas Huizinga⁶, Yann Abraham⁷ and Rachel Knevel¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ³King's College London, London, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵Pfizer Inc., Cambridge, MA, ⁶Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁷Janssen Research and Development, Beerse, Belgium
Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
Abstract Number: 0512 • ACR Convergence 2024
Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Jasmine Shwetar¹, William Rigby², Sladjana Skopelia-Gardner³, Abhimanyu Armarnani¹, Kelly Ruggles¹ and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Dartmouth-Hitchcock, Norwich, VT, ³Dartmouth Hitchcock Medical Center, Hanover, NH
Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…
Abstract Number: 0530 • ACR Convergence 2024
Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein², Marike van der Leeden², Franktien Turkstra², Jos Twisk³, Maarten Boers³, Henriët van Middendorp⁴, Peter Weijs⁵ and Dirkjan van Schaardenburg⁶, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁴Leiden University, Leiden, Netherlands, ⁵Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Jia Shi¹, Yang Wu¹, Ting Wang², Chen Yu³, qian wang⁴, Xinping Tian⁵, Mengtao Li⁴, Kristen Demoruelle⁶, Joshua Solomon⁷ and Christian Lood², ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷National Jewish Health, Denver, CO
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…
Abstract Number: 0894 • ACR Convergence 2024
HOXD13 Regulation of Primary Cilia in Rheumatoid Arthritis Synovial Fibroblasts: Implications for Joint-Specific Pathogenesis
Masoumeh Mirrahimi¹, Kerstin Klein², Alexandra Khmelevskaya³, Eva Camarillo Retamosa³, Miranda Houtmen³, Oliver Distler¹ and Caroline Ospelt¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²University of Bern, Bern, Switzerland, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) follows a characteristic pattern of joint involvement. The embryonic development of limbs and joints influences certain joints' propensity to develop arthritis.…
Abstract Number: 0945 • ACR Convergence 2024
Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice
Eri Watanabe¹, Junko Nishio¹, Tatsuma Ban², Zento Yamada¹, Tomohiko Tamura² and Toshihiro Nanki¹, ¹Toho University, Tokyo, Japan, ²Yokohama City University, Yokohama, Japan
Background/Purpose: There has been accumulating evidence that cellular senescence of fibroblasts and alveolar epithelial cells contributes to inflammation and fibrosis through a senescence-associated secretory phenotype…
Abstract Number: 1014 • ACR Convergence 2024
Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes
Sumanth Chandrupatla¹ and Jasvinder Singh², ¹University of Alabama at Birmingham, Birmingham, AL, ²Baylor College of Medicine, Birmingham, AL
Background/Purpose: We aimed to assess whether there is a rural-urban disparity in the incidence of myocardial infarction (MI) hospitalization in patients with rheumatoid arthritis (RA).Methods:…
Abstract Number: 1056 • ACR Convergence 2024
Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
Roya Hosseini¹, Lawrence Brown¹, Marc Fleming¹, Rosa Rodriguez-Monguio² and Enrique Seoane-Vazquez¹, ¹Chapman University School of Pharmacy, Irvine, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) treatment has been revolutionized by the development of biologic disease-modifying antirheumatic drugs (bDMARDs), which are increasingly used. The high cost of…
Abstract Number: 1328 • ACR Convergence 2024
Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
Roslin Jose George¹, Noah Frechette¹, Iqra Javed¹, Bradly Kimbrough², Sara Achenbach³, Elena Joerns¹, Vanessa Kronzer¹, John Davis¹, Cynthia Crowson¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA…
Abstract Number: 1344 • ACR Convergence 2024
Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
Rathnam Venkat¹, Keigo Hayashi², Pierre-Antoine Juge³, Gregory McDermott², Misti Paudel⁴, Xiaosong Wang⁵, Kathleen Vanni⁵, Emily Kowalski⁶, Grace Qian⁵, Katarina Bade⁶, Alene Saavedra⁶, Kevin Mueller⁶, Sung Hae Chang⁷, Paul Dellaripa⁶, Michael Weinblatt⁸, Nancy Shadick⁵, Tracy J Doyle⁹, Philippe Dieudé¹⁰ and Jeffrey Sparks¹¹, ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women’s Hospital, Brookline, MA, ³Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham and Women's Hospital, West Roxbury, MA, ¹⁰Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous with about half of patients having progressive disease. However, the rates of progression and the association…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1376 • ACR Convergence 2024
Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010
Catherine Emanuel¹ and Ajay Aggarwal², ¹Aclaris Therapeutics Inc., St Louis, MO, ²Aclaris Therapeutics, Inc., Wellesley, MA
Background/Purpose: Varying mechanisms of action are required to address the needs of rheumatoid arthritis patients with different levels of severity. Since 2010, all new FDA…
Abstract Number: 1393 • ACR Convergence 2024
Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Roy Fleischmann¹, Zoltán Szekanecz², Eduardo Mysler³, Kevin Winthrop⁴, Kunihiro Yamaoka⁵, Kirsten Famulla⁶, Yanna Song⁷, Birgit Kovacs⁷, Sander Strengholt⁸ and Gerd Burmester⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Debrecen, Debrecen, Hungary, ³Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵Kitasato University School of Medicine, Sagamihara, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁷AbbVie, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].